Abstract
SUMMARYIndividual participant data (IPD) from completed oncology clinical trials are a valuable but rarely available source of information. A lack of minable survival distributions has made it difficult to identify factors determining the success and failure of clinical trials and improve trial design. We imputed survival IPD from ∼500 arms of phase III oncology trials (representing ∼220,000 events) and found that they are well fit by a two-parameter Weibull distribution. This makes it possible to use parametric statistics to substantially increase trial precision with small patient cohorts typical of phase I or II trials. For example, a 50-person trial parameterized using Weibull distributions is as precise as a 90-person trial evaluated using traditional statistics. Mining IPD also showed that frequent violations of the proportional hazards assumption, particularly in trials of immune checkpoint inhibitors (ICIs), arise from time-dependent therapeutic effects and hazard ratios. Thus, the duration of ICI trials has an underappreciated impact on the likelihood of their success.
Publisher
Cold Spring Harbor Laboratory
Reference77 articles.
1. Akaike, H. , Petrov, B.N. , and Csaki, F . (1973). Second international symposium on information theory (Akadémiai Kiadó, Budapest).
2. Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy;N. Engl. J. Med,2018
3. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2);The Lancet,2015
4. Arfè, A. , Alexander, B. , and Trippa, L. (2020). Optimality of testing procedures for survival data in the nonproportional hazards setting. Biometrics biom.13315.
5. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma